TREX1 and diffuse large B-cell lymphoma: The identification of an inactivating somatic mutation in TREX1 in DLBCL/HGBL may prompt a retrospective analysis of existing omics data from DLBCL/HGBL patient samples, potentially leading to the organization of clinical trials evaluating STING agonists in the context of these diseases [66,67,68].